Lasmiditan Increases Odds of Freedom From Migraine Attacks
Lasmiditan is associated with greater odds of achieving pain freedom from migraine attacks compared with placebo.
Pain Management
Managing Analgesia in Critically Ill Patients Receiving Naltrexone
Researchers convened to develop recommendations on management of sedation and analgesia in critically ill patients receiving naltrexone for opioid use disorder.
FDA: Stimulation Trial Should Be Performed Before Implanting SCS for Pain
The FDA reported that between July 27, 2016 and July 27, 2020, a total of 107,728 medical device reports (MDRs) associated with SCS devices intended for pain were received.
Qdolo Approved for Pain Management
Qdolo contains tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin reuptake.
Orphengesic Forte Now Available for Pain Management
The safety of long-term Orphengesic Forte use has not been established.
New IV Opioid Analgesic Approved for Acute Pain
Olinvyk is indicated for short-term intravenous use in hospitals or other controlled clinical settings.
Best Practices for Chronic Pain Fellows During the COVID-19 Pandemic
Recommendations for addressing mental health among pain management fellows during the COVID-19 pandemic.
Qutenza Approved for Painful Diabetic Peripheral Neuropathy of the Feet
The FDA has approved Qutenza® for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet.
Therapeutic Levels of THC for Pain Reduction in Diabetic Neuropathy
These results that there is a therapeutic window of THC concentrations for treatment of painful diabetic neuropathy.
Narcotic Analgesics
A comparative chart of narcotic analgesics including formulations, strengths, and dosing intervals.
-
Loading...
-
Loading...
